Literature DB >> 218750

Suppression of plasma ACTH concentration by angiotensin II infusion in normal humans and in a subject with a steroid 17 alpha-hydroxylase defect.

P F Semple, J C Buckingham, P A Mason, R Fraser.   

Abstract

Six healthy subjects were infused with angiotensin II and plasma concentrations of angiotensin, ACTH and cortisol were measured before, during and after the infusion. In all cases the plasma ACTH concentration fell as plasma angiotensin increased and rose again, sometimes to higher than basal levels, when the angiotensin infusion was terminated. These effects were most marked at the highest rate of infusion (8 pmol/kg/min) and, at the lower rates (2 and 4 pmol/kg/min), there was some recovery of ACTH levels during the infusion period in some subjects. Plasma ACTH concentrations also fell when angiotensin was infused into a patient with high ACTH levels due to a steroid 17 alpha-hydroxylation defect. The inhibition of ACTH secretion is not due to a rise in plasma cortisol operating a negative feedback inhibition. It could be a direct effect of the infused angiotensin on the brain-hypothalamus-pituitary complex or an effect on the metabolism of ACTH.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218750     DOI: 10.1111/j.1365-2265.1979.tb01359.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  The effect of the calcium antagonist nifedipine on pressor and aldosterone responses to angiotensin II in normal man.

Authors:  J A Millar; K A McLean; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Release of beta-lipotropin- and beta-endorphin-like material induced by angiotensin in the conscious rat.

Authors:  U Beuers; G Hertting; W Knepel
Journal:  Br J Pharmacol       Date:  1982-08       Impact factor: 8.739

3.  Evaluation of anterior pituitary function in hypertensive patients following inhibition of angiotensin II generation.

Authors:  S Alagna; P Dessy-Fulgheri; A Masala; P Madeddu; P P Rovasio; N Glorioso; A Rappelli
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.